ERBB2 and breast cancer: Although fulvestrant 250 mg is adequate to competitively inhibit binding of estradiol to ER, inhibition of ER transcription may occur without a complete degradation of receptor.12 In continuation, supporting evidence showing the effect of fulvestrant dose on efficacy in patients with HR+/HER2− advanced BC began emerging.